Solid Tumor Oncology
Clinical research at Centre Leon Berard includes a broad set of advanced and metastatic solid tumors, with particular attention to gastroesophageal adenocarcinoma, pancreatic adenocarcinoma, renal cell carcinoma, and gynecological cancers. The portfolio also covers rare and molecularly defined cancers, including tumors with FGFR2b overexpression and MSI/dMMR or EBV-associated disease.
- Metastatic gastric and esophageal cancer
- Pancreatic cancer
- Renal cell carcinoma
- Molecularly selected solid tumors
Research also extends to patients with recurrent or treatment-resistant disease, reflecting interest in cancers requiring targeted and immunologic strategies.
Sarcoma and Gastrointestinal Stromal Tumor Research
A major area of interest is sarcoma, including soft tissue sarcomas, bone sarcomas, rare sarcomas, and gastrointestinal stromal tumor (GIST) across localized, unresectable, and metastatic settings. The clinical program also includes low-grade endometrial stromal sarcoma and other uncommon mesenchymal malignancies.
- Soft tissue sarcomas
- Bone sarcomas
- Rare sarcomas
- GIST
These studies address treatment resistance, maintenance strategies, and disease control in tumors with limited therapeutic options.
Neurologic and Central Nervous System Tumors
The sponsor supports research in central nervous system malignancies, including high-grade brain tumors, glioma, and ependymoma in children, adolescents, and adults. This area also includes tumors of the spinal cord and other intracranial sites, with interest in both newly diagnosed and progressive disease.
- High-grade brain tumors
- Glioma
- Ependymoma
- Spinal and intracranial tumors
Clinical activity in this domain reflects a focus on difficult-to-treat neuro-oncology populations and histology-specific treatment approaches.
Hematologic Malignancies and Germ Cell Tumors
Research includes acute myeloid leukemia and seminoma, with attention to both refractory blood cancers and localized germ cell tumors. The portfolio also spans patients with disease recurrence risk after curative treatment, supporting studies in settings where relapse prevention is clinically important.
- Acute myeloid leukemia
- Seminoma
- Relapse-risk oncology
These trials reflect interest in hematologic and germ cell malignancies that require tailored therapeutic strategies.
Head and Neck, Vulvar, and Gynecologic Oncology
The sponsor is active in head and neck squamous cell carcinoma, vulvar squamous cell carcinoma, and gynecologic cancer, including metastatic disease and rare histologic subtypes. This includes work in oropharyngeal, laryngeal, and hypopharyngeal cancers, as well as endometrial and other hormone-responsive malignancies.
- Head and neck squamous cell carcinoma
- Vulvar squamous cell carcinoma
- Endometrial stromal sarcoma
- Gynecologic cancer
Research in these areas includes tumors managed in the curative and advanced settings, with emphasis on disease-specific therapeutic development.
